Sweden-headquartered IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, has announced that the company will present at the event Life Science-dagen in Gothenburg on March 6. The company will also participate in a fireside chat with ABG, to be published on March 6.
At Life Science-dagen in Gothenburg, the company will be presented by Viktor Siewertz, CFO at IRLAB, who will give a 20 minutes presentation of the company followed by a 10 minutes Q&A at 09:15–09:45. The event will be live streamed and can be viewed afterwards on the event website.
The fireside chat hosted by ABG will be a conversation between Viktor Siewertz, CFO at IRLAB and ABG’s analyst. The conversation will be recorded and published on ABG’s website for commissioned research during March 6, 2024.
IRLAB has its origin in Nobel Laureate Prof. Arvid Carlsson's research group and the discovery of a connection between the brain's neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed phase IIb and is in preparation toward phase III. Pirepemat (IRL752), is currently in phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson's disease. In addition, the company is also progressing the three preclinical programs IRL757 (financially supported by the Michael J. Fox Foundation), IRL942, and IRL1117 towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based Integrative Screening Process (ISP) research platform.
|